The Vancomycin Symposium: Summary and Comments
The Vancomycin Symposium: Summary and Comments
复制标题
万古霉素研讨会：总结和评论
DOI：
10.1093/clinids/3.supplement.s293
复制
发表时间：
1981
期刊：
影响因子：
--
通讯作者：
R. Wise
中科院分区：
文献类型：
--
作者：
R. Wise
本次研讨会的目的是回顾和讨论有关万古霉素的数据，万古霉素是一种抗生素，于 1956 年引入临床医学，距青霉素引入民用医疗实践约 14 年。 1942 年从流行感染中分离出的金黄色葡萄球菌培养物对浓度低至 0.06 单位/毫升的青霉素敏感。在接下来的几年中，越来越多的金黄色葡萄球菌分离株被发现对青霉素具有耐药性。链霉素、金霉素、土霉素、氯霉素、杆菌肽、红霉素和新霉素的引入为葡萄球菌感染的治疗提供了额外的抗菌药物，特别是对青霉素耐药的葡萄球菌感染。由于耐药菌株的迅速出现，二氢链霉素和链霉素不适合长期使用。对四环素、氯霉素和红霉素耐药的菌株数量不断增加，有时会迫使临床医生使用毒性更强的抗生素、杆菌肽和新霉素进行胃肠外给药，尽管会出现可预见的不良并发症。
The purpose of this symposium was the review and the discussion of data that has been developed regarding vancomycin, an antibiotic that was introduced into clinical medicine in 1956, approximately 14 years after the introduction of penicillin into civilian medical practice. Cultures of Staphylococcus aureus, which had been isolated from prevalent infections in 1942, were susceptible to penicillin in concentrations as low as 0.06 units/ml. During the following years, increasing numbers of isolates of S. aureus were found to be resistant to penicillin. The introduction of streptomycin, chlortetracycline, oxytetracycline, chloramphemicol, bacitracin, erythromycin, and neomycin provided additional antibacterial drugs for the treatment of staphylococcal infections, particularly those resistant to penicillin. Dihydrostreptomycin and streptomycin were not desirable for long-term use because of the rapid appearance of resistant strains. Appearance of increasing numbers of strains resistant to the tetracyclines, chloramphenicol, and erythrymycin occasionally forced clinicians to use parenteral administration of the more toxic antibiotics, bacitracin and neomycin, in spite of predictable adverse complications.